TY - JOUR
T1 - Assessing the health of the nephron in acute kidney injury
T2 - Biomarkers of kidney function and injury
AU - Menez, Steven
AU - Parikh, Chirag R.
N1 - Funding Information:
S.M. is supported by NIH T32 grant (HL007024). C.R.P. is supported by NIH grant K24-DK-090203 and the P30-DK-079310-07 O’Brien Kidney Center Grant. C.R.P. is a member of the NIH-sponsored Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) Consortium (U01-DK-082185).
Funding Information:
S.M. is supported by NIH T32 grant (HL007024). C.R.P. is supported by NIH grant K24-DK-090203 and the P30-DK-079310-07 O'Brien Kidney Center Grant. C.R.P. is a member of the NIH-sponsored Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) Consortium (U01-DK-082185).
Publisher Copyright:
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Purpose of reviewSerum creatinine and urine output continue to be the mainstays of diagnosis of acute kidney injury, though both of these measures have significant limitations, especially in acutely hospitalized patients. Biomarkers in both blood and urine have been studied extensively in the research setting and are on the verge of clinical practice to improve diagnosis of AKI.Recent findingsBlood and urine biomarkers can be localized to specific areas or functions within the nephron. Biomarkers can help to characterize glomerular or tubular function; glomerular, tubular, or interstitial injury; inflammation; or repair. Further, biomarkers can improve diagnosis of AKI in various clinical settings including acute interstitial nephritis, acute tubular injury, and hepatorenal syndrome, and cardiorenal syndrome.SummaryBiomarkers are becoming more prevalent in both research and getting close to clinical use. Both blood and urine biomarkers can help to localize impairment in nephron health by either location or function within the nephron and among various causes of AKI.
AB - Purpose of reviewSerum creatinine and urine output continue to be the mainstays of diagnosis of acute kidney injury, though both of these measures have significant limitations, especially in acutely hospitalized patients. Biomarkers in both blood and urine have been studied extensively in the research setting and are on the verge of clinical practice to improve diagnosis of AKI.Recent findingsBlood and urine biomarkers can be localized to specific areas or functions within the nephron. Biomarkers can help to characterize glomerular or tubular function; glomerular, tubular, or interstitial injury; inflammation; or repair. Further, biomarkers can improve diagnosis of AKI in various clinical settings including acute interstitial nephritis, acute tubular injury, and hepatorenal syndrome, and cardiorenal syndrome.SummaryBiomarkers are becoming more prevalent in both research and getting close to clinical use. Both blood and urine biomarkers can help to localize impairment in nephron health by either location or function within the nephron and among various causes of AKI.
KW - acute interstitial nephritis
KW - acute kidney injury
KW - acute tubular necrosis
KW - biomarkers
KW - cardiorenal syndrome
KW - hepatorenal syndrome
KW - precision medicine
UR - http://www.scopus.com/inward/record.url?scp=85072905099&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072905099&partnerID=8YFLogxK
U2 - 10.1097/MNH.0000000000000538
DO - 10.1097/MNH.0000000000000538
M3 - Article
C2 - 31369422
AN - SCOPUS:85072905099
SN - 1062-4821
VL - 28
SP - 560
EP - 566
JO - Current opinion in nephrology and hypertension
JF - Current opinion in nephrology and hypertension
IS - 6
ER -